|Over a week ago|
Kaleido Biosciences CEO Alison Lawton to step down » 16:4606/1606/16/20
Kaleido Biosciences announced that Alison Lawton has chosen to step down from her position as President and CEO in order to return to the United Kingdom and attend to an unexpected family health matter. Lawton will continue to serve as a Director and special advisor to Kaleido and will support the company through this transition. Kaleido's Board of Directors will be initiating a search for a new CEO and has established an Office of the CEO to lead the organization and to advance its strategic goals during this transition period. The Office of the CEO will be comprised of Mike Bonney and Lawton. Bonney is the Executive Chair and former CEO of Kaleido and has more than 25 years of experience leading biotechnology and pharmaceutical companies, including 12 years as the CEO of Cubist Pharmaceuticals. Other members of the Board of Directors have also committed to providing their expertise and support to the organization until a successor CEO is identified.
Goldman Sachs to hold a virtual conference » 08:4706/1106/11/20
HUM, DTIL, CHNG, ALKS, ALNY, HCAT, KLDO, ZEAL, GOSS, MRNA, ORTX, BMY, ADVM, BCYC, ESPR, PHAT, INSP, UBX, PHG, ATRA
41st Annual Global…
41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link
Fly Insider: Danaher, AMD among week's notable insider transactions » 13:2906/0806/08/20
NKLA, CBAT, KLDO, LJPC, DHR, ACMR, AMD, APO, BLL, ANGI
Welcome to "Fly Insider,"…
|Over a month ago|
Kaleido Biosciences 4.75M share Spot Secondary priced at $7.50 » 06:1406/0206/02/20
Morgan Stanley acted as…
Morgan Stanley acted as lead book running manager for the offering.
Kaleido Biosciences announces $30M common stock offering » 16:1906/0106/01/20
Kaleido Biosciences announced that it intends to sell, subject to market and other conditions, $30M of shares of its common stock in an underwritten public offering. Kaleido intends to use the net proceeds from the offering, in addition to its existing cash resources, to fund its continued research and development activities, including the ongoing clinical program of KB109 in patients with mild-to-moderate COVID-19, the ongoing Phase 2 clinical trial of KB195 in patients with urea cycle disorders, and the planned clinical study of KB295 in patients with mild-to-moderate ulcerative colitis, to fund any other research and development activities that relate to its current and future clinical and preclinical activities, and the remainder for planned general and administrative expenses, working capital and other general corporate purposes. Morgan Stanley is acting as sole book-running manager for the offering. Canaccord Genuity is acting as lead manager for the offering.
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs » 07:5305/2105/21/20
As previously reported,…
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Kaleido Biosciences to Equal Weight from Overweight with a price target of $8, down from $15. Initial proof-of-concept data has been encouraging for Kaleido's MMT product candidates for hyperammonemia programs targeting urea cycle disorders and hepatic encephalopathy, but data from the Phase 2 program in UCD will be further delayed to the second half of 2021 due to the impact of COVID-19, Harrison tells investors. While an understandable consequence of COVID-19, he thinks its best to move to a lower rating pending greater certainty regarding a readout for KB195 in UCD and a more defined timeline towards data for KB174 in hyperammonemia, Harrison said.
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley » 05:2005/2105/21/20
Morgan Stanley analyst…
Morgan Stanley analyst Matthew Harrison downgraded Kaleido Biosciences to Equal Weight from Overweight with an $8 price target.
Kaleido Biosciences begins clinical study of KB109 in COVID-19 patients » 06:3905/1405/14/20
Kaleido Biosciences initiated a controlled clinical study evaluating Microbiome Metabolic Therapy candidate KB109 added to Supportive Self-Care for outpatients who are positive for SARs-Cov-2 infection with mild-to-moderate COVID-19. "The burden of the COVID-19 pandemic on patients and healthcare facilities is vast, and there remains a need for interventional studies evaluating patients with mild-to-moderate disease, which represents the majority of infections," said Chief Medical Officer and Head of Research & Development Katharine Knobil. "We have evidence from our ex vivo research that KB109 increases the production of metabolites that have been shown to improve the immune response in viral respiratory infections. Published data suggest these metabolites may prevent an overaggressive immune response to COVID-19 and avoid more serious complications of this infection. Because of the favorable safety profile of KB109, we are able to rapidly initiate this very important clinical study. We look forward to exploring the potential of KB109 in COVID-19 as well as expanding our understanding of its applicability to other infections." The studies will include assessment of clinical outcomes, healthcare utilization, and biomarkers of the inflammatory response that will inform the potential of KB109 in COVID-19 as well as other viral and bacterial infections. Top-line data from the multi-center study are expected in Q4.
Kaleido Biosciences reports Q1 EPS (64c), consensus (64c) » 06:3605/1405/14/20
As of March 31, the…
As of March 31, the company reported cash and cash equivalents of $53.8M. Kaleido has extended its cash runway further into the first quarter of 2021.CEO Alison Lawton said, "We are fortunate that our product platform and efficient development model provide Kaleido flexibility in responding to the current situation. We have rapidly initiated new clinical programs aimed at addressing the unmet need for outpatients with mild-to-moderate COVID-19 disease and are further exploring the potential of MMTs in immune-mediated and inflammatory diseases in ulcerative colitis. We anticipate data readouts from these and other programs starting in Q4 2020 and throughout 2021". "
|Over a quarter ago|
Kaleido Biosciences appoints Anne Prener to board of directors » 08:3904/0304/03/20
Kaleido Biosciences announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors. Prener has more than 25 years of leadership experience within life sciences companies, and recently served as CEO of Freeline Ltd.